Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash
The cash transaction leaves Adia Med with a majority economic interest, subject to Live Oak's option to acquire additional units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adia Med (OTCQB: ADIA) completed the sale of an economic interest in Adia Labs to CEO Larry Powalisz for $350,000 in cash. Powalisz purchased seven membership units representing a 7% economic interest at $50,000 per unit. That price matches the per-unit price in the company's recent sale of a 30% interest to Live Oak Health, doing business as QCM Biologics.
Adia Med retains a majority economic interest following closing, subject to the prior Live Oak transaction and any future exercise of Live Oak's option to acquire additional units. Independent directors approved the sale, and Live Oak consented. Use of the proceeds requires independent director approval. The purchased units are intended to carry 7% of total voting power on member matters; the parties will take reasonably necessary steps to reflect that power in company records and the operating agreement.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointCompleted sale to CEO Larry Powalisz brings Adia Med $350,000 in cash. 2.9% of market cap
Negative
- Moderate point7% economic interest in Adia Labs sold to Powalisz reduces Adia Med's ownership.
- Minor point. Forward-looking: it has not happened yet and may not happen.Live Oak's option permits acquisition of additional units, leaving Adia Med's retained interest subject to future exercise.
- Minor pointUse of proceeds remains subject to independent director approval.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Winter Park, Florida--(Newsfile Corp. - October 20, 2026) - Adia Med, Inc. (OTCQB: ADIA) today announced that its Chief Executive Officer, Larry Powalisz, purchased a
Adia Med Sells
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/319712_adiamed.jpg
The per-unit purchase price is consistent with the price used in the Company's recent sale of a
The transaction was approved by Adia Med's independent directors and received the consent of Live Oak Health LLC. Use of the proceeds is subject to independent director approval. The purchased units are intended to carry
"I'm putting my own money into Adia Labs because I believe in what we're building," said Larry Powalisz, Chief Executive Officer of Adia Med. "This investment reflects my confidence in the business, the team, and the long-term opportunity we see ahead."
The units are restricted membership interests and have not been registered under the Securities Act of 1933.
Adia Labs products, including AdiaVita and AdiaLink, are not FDA-approved to diagnose, treat, cure, or prevent any disease.
The Company's Form 8-K relating to the transaction is available at www.sec.gov.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.
About Adia Med Inc.
Adia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company built around active, IRB-approved stem cell therapy studies. Through its Adia Med clinics, the company delivers stem cell treatments alongside complementary services like platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies, The current studies are targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. Its Adia Labs division manufactures regenerative products (AdiaVita, AdiaLink) that supply this clinical work.
Adia Labs generates revenue by manufacturing and selling regenerative products (AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments (stem cell therapies, PRP, TPE, and aHSCT). Additional revenue comes from the company's
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319712
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Adia Med's CEO pay for the Adia Labs interest?
Larry Powalisz paid $350,000 in cash for a 7% economic interest in Adia Labs. The completed purchase covered seven membership units at $50,000 per unit, matching the per-unit price of the recent sale to Live Oak Health.